Conference Presentation: Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Trial

In this randomized, double-blind, placebo-controlled, dose-finding adaptive phase 2a/2b trial, treatment with human recombinant alkaline phosphatase did not improve kidney function among critically ill patients with sepsis-associated acute kidney injury (AKI). Peter Pickkers, MD, PhD, of Radboud University Nijmegen Medical Center, the Netherlands, presents findings from the STOP-AKI trial at the European Society of Intensive Care Medicine (ESICM) 31st Annual Congress, LIVES 2018, on October 24 in Paris. Used with permission.